Dextromethorphan: An update on its utility for neurological and neuropsychiatric disorders
Dextromethorphan (DM) is a commonly used antitussive and is currently the only FDA-approved pharmaceutical treatment for pseudobulbar affect. Its safety profile and diverse pharmacologic actions in the central nervous system have stimulated new interest for repurposing it. Numerous preclinical investigations and many open-label or blinded clinical studies have demonstrated its beneficial effects across a variety of neurological and psychiatric disorders. However, the optimal dose and safety of chronic dosing are not fully known. This review summarizes the preclinical and clinical effects of DM and its putative mechanisms of action, focusing on depression, stroke, traumatic brain injury, seizure, pain, methotrexate neurotoxicity, Parkinson's disease and autism. Moreover, we offer suggestions for future research with DM to advance the treatment for these and other neurological and psychiatric disorders.
Digital Commons Citation
Nguyen, L; Thomas, K L.; Lucke-Wold, B P.; and Cavendish, J Z., "Dextromethorphan: An update on its utility for neurological and neuropsychiatric disorders" (2016). Clinical and Translational Science Institute. 989.